Yoshie Morimoto

708 total citations
25 papers, 408 citations indexed

About

Yoshie Morimoto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Yoshie Morimoto has authored 25 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in Yoshie Morimoto's work include Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (15 papers) and Lung Cancer Research Studies (10 papers). Yoshie Morimoto is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (15 papers) and Lung Cancer Research Studies (10 papers). Yoshie Morimoto collaborates with scholars based in Japan and United Kingdom. Yoshie Morimoto's co-authors include Koichi Takayama, Masahiro Iwasaku, Tadaaki Yamada, Yoshiko Kaneko, Junji Uchino, Yusuke Chihara, Keisuke Onoi, Takayuki Shimamoto, Osam Mazda and Tsunao Kishida and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Cancer Letters and Cancer Treatment Reviews.

In The Last Decade

Yoshie Morimoto

24 papers receiving 402 citations

Peers

Countries citing papers authored by Yoshie Morimoto

Since Specialization

Citations

This map shows the geographic impact of Yoshie Morimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshie Morimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshie Morimoto more than expected).

Fields of papers citing papers by Yoshie Morimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshie Morimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshie Morimoto. The network helps show where Yoshie Morimoto may publish in the future.

Co-authorship network of co-authors of Yoshie Morimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshie Morimoto. A scholar is included among the top collaborators of Yoshie Morimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshie Morimoto. Yoshie Morimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety of First-Line Nivolumab Plus Ipilimumab in Very Old (≥ 80 Years) Patients With Unresectable Malignant Pleural Mesothelioma: A Retrospective Single-Center Case Series 2024 ·Cureus ·Takayuki Shimamoto, Yoshie Morimoto, (unknown), Rie Yoshida, (unknown)	0
2	Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells 2022 ·Cancer Medicine ·Yuki Katayama, Tadaaki Yamada, Shinsaku Tokuda, (unknown), Naoya Nishioka, Kenji Morimoto, Keiko Tanimura, Yoshie Morimoto, Masahiro Iwasaku, Mano Horinaka, Toshiyuki Sakai, Kenji Kita, Seiji Yano, Koichi Takayama	5
3	A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC 2022 ·JTO Clinical and Research Reports ·Kenji Morimoto, Ryo Sawada, Tadaaki Yamada, Koichi Azuma, Kentaro Ito, Yasuhiro Gotô, Hideharu Kimura, Taishi Harada, Shinsuke Shiotsu, Nobuyo Tamiya, Yusuke Chihara, Takayuki Takeda, Osamu Hiranuma, Isao Hasegawa, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama	5
4	Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study 2022 ·JTO Clinical and Research Reports ·Kenji Morimoto, Tadaaki Yamada, Takayuki Takeda, Shinsuke Shiotsu, (unknown), Taishi Harada, Nobuyo Tamiya, Yusuke Chihara, Osamu Hiranuma, Takahiro Yamada, (unknown), Takayuki Nakano, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama	7
5	A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors 2022 ·International Immunopharmacology ·Kenji Morimoto, Tadaaki Yamada, Yoshie Morimoto, Takeshi Ishikawa, Jun Asai, Atsuko Fujihara, Akihito Arai, Norito Katoh, Osamu Ukimura, Shigeru Hirano, Yoshito Itoh, Koichi Takayama	5
6	Changes in serum transforming growth factor-beta concentration as a predictive factor for radiation-induced lung injury onset in radiotherapy-treated patients with locally advanced lung cancer 2022 ·Translational Lung Cancer Research ·(unknown), Yoshiko Kaneko, (unknown), Daisuke Shimizu, Yoshie Morimoto, Shinsaku Tokuda, Masahiro Iwasaku, Tadaaki Yamada, Koichi Takayama	8
7	Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study 2021 ·OncoImmunology ·Kenji Morimoto, Junji Uchino, Takashi Yokoi, Takashi Kijima, Yasuhiro Gotô, Akira Nakao, Makoto Hibino, Takayuki Takeda, Hiroyuki Yamaguchi, (unknown), Masafumi Takeshita, Yusuke Chihara, Takahiro Yamada, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama	33
8	Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients 2021 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Tadaaki Yamada, Kenji Morimoto, Akira Nakao, Yasuhiro Gotô, (unknown), Takayuki Takeda, (unknown), Keisuke Onoi, Yusuke Chihara, (unknown), Takahiro Yamada, Osamu Hiranuma, Satomi Tanaka, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Yoshiko Kaneko, Junji Uchino, Koichi Takayama	1
9	Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer 2021 ·Cancer Letters ·Keiko Tanimura, Tadaaki Yamada, Mano Horinaka, Yuki Katayama, (unknown), Kenji Morimoto, Takayuki Nakano, Shinsaku Tokuda, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Kazue Yoneda, Seiji Yano, Toshiyuki Sakai, Koichi Takayama	12
10	Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study 2021 ·Thoracic Cancer ·(unknown), Kenji Morimoto, Tadaaki Yamada, Shinsuke Shiotsu, Yusuke Chihara, Takahiro Yamada, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Takayuki Takeda, Koichi Takayama	11
11	Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer 2021 ·Lung Cancer ·Kenji Morimoto, Tadaaki Yamada, Takashi Yokoi, Takashi Kijima, Yasuhiro Gotô, Akira Nakao, Makoto Hibino, Takayuki Takeda, Hiroyuki Yamaguchi, (unknown), Masafumi Takeshita, Yusuke Chihara, (unknown), (unknown), Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Koichi Takayama	39
12	Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study 2021 ·Journal of Cancer Research and Clinical Oncology ·Kenji Morimoto, Junji Uchino, Takashi Yokoi, Takashi Kijima, Yasuhiro Gotô, Akira Nakao, Makoto Hibino, Takayuki Takeda, Hiroyuki Yamaguchi, (unknown), Masafumi Takeshita, Yusuke Chihara, Takahiro Yamada, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama	1
13	Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study 2021 ·Translational Lung Cancer Research ·(unknown), Yoshiko Kaneko, (unknown), Hiroyuki Fujii, Satomi Tanaka, Shinsuke Shiotsu, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Tadaaki Yamada, Junji Uchino, Koichi Takayama	4
14	Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study 2021 ·Frontiers in Oncology ·Kenji Morimoto, Tadaaki Yamada, (unknown), (unknown), (unknown), Takayuki Takeda, Keisuke Onoi, Yusuke Chihara, (unknown), (unknown), (unknown), Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Koichi Takayama	26
15	The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study 2021 ·Frontiers in Oncology ·Keiko Tanimura, Tadaaki Yamada, (unknown), Shinsuke Shiotsu, (unknown), Takayuki Takeda, (unknown), (unknown), (unknown), Mayumi Takeuchi, Yusuke Chihara, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Koichi Takayama	12
16	Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review 2020 ·Journal of Clinical Medicine ·(unknown), Mai Asano, Junji Uchino, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Tadaaki Yamada, Michiaki Fukui, Koichi Takayama	20
17	Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients 2020 ·Medical Oncology ·Kenji Morimoto, Tadaaki Yamada, (unknown), Yuki Katayama, Satomi Tanaka, (unknown), Noriya Hiraoka, (unknown), Takayuki Takeda, Keisuke Onoi, Yusuke Chihara, (unknown), Takahiro Yamada, (unknown), Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Koichi Takayama	12
18	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review 2020 ·Journal of Clinical Medicine ·Keisuke Onoi, Yusuke Chihara, Junji Uchino, Takayuki Shimamoto, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama	117
19	Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells 2018 ·Biochemical and Biophysical Research Communications ·Yoshie Morimoto, Tsunao Kishida, (unknown), Koichi Takayama, Osam Mazda	55
20	Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer 2018 ·Anticancer Research ·(unknown), Yusuke Chihara, Yoshie Morimoto, Keiko Tanimura, Tatsuya Imabayashi, (unknown), Yoshiko Kaneko, (unknown), Mikio Ueda, (unknown), Yoshinobu Iwasaki, Koichi Takayama	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact